Piśmiennictwo:
1. Osmon DR. Antimicrobial prophylaxis in adults. Mayo Clin Proc 2000;75:98-109.
2. Crabtree TD, Pelletier SJ, Gleason TG, et al. Clinical characteristics and antibiotic utilization in surgical patients with Clostridium difficile-associated diarrhea. Am Surg 1999;65(6):507-511.
3. US Food and Drug Administration (FDA). Information for healthcare professionals: fluoroquinolone antimicrobial drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR),
gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]: tendonitis risk black box warning, 7/8/2008; 2008. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm089652.htm. Accessed May 20, 2011.
4. Gerber MA, Baltimore R, Eaton C, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Diseases in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation 2009;119:1541-1551.
5. Baddour LM. Cellulitis and erysipelas. In: Baron EL, ed. UpToDate; 2008.
6. Pasternack MS, Swartz MN. Cellulitis, necrotizing fasciitis, and subcutaneous tissue infections. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practices of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:1289-1312.
7. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-1406.
8. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant S aureus infections in adults and children. Clin Infect Dis 2011;52(3):e8-e55.
9. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA 1988;260:2682-2685.
10. Baddour LM, Epstein AE, Erickson CC, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Interdisciplinary Council on Quality of Care and Outcomes Research. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010;121:458-477.
11. Centers for Disease Control and Prevention (CDC). Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-5):1-10.
12. Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43(12):1499-1539.
13. Stapleton A, Stamm W. Prevention of urinary tract infection. Infect Dis Clin North Am 1997;11:719-733.
14. Gupta K, Hooton TM, Roberts PL, et al. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 2001;135:9-16.
15. Melekos MD, Asbach HW, Gerharz E, et al. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol 1997;157:935-939.
16. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49(6):2087-2107.
17. Moran GJ, Talan DA, Abrahamian FM. Antimicrobial prophylaxis for wounds and procedures in the emergency department. Infect Dis Clin North Am 2008;22:117-143.
18. Endom EE. Initial management of animal and human bites (V.18.3). UpToDate. 2010. http://www.uptodate.com/contents/initial-management-of-animal-and-human-bites?source=search_result&selectedTitle=4%7E150. Accessed May 20, 2011.
19. Goldstein EJC. Bites. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practices of Infectious Diseases. Vol 2. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:3911-3915.
20. Centers for Disease Control and Prevention (CDC). Recommended antimicrobial agents for treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Morb Mortal Wkly Rep 2005;54:1-15.
21. Antiviral drugs for influenza. Med Lett Drugs Ther 2009;51(1325):89-92.
22. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children: diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009;48(8):1003-1032.
23. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea [published correction appears in Ann Intern Med2005;143(3):239]. Ann Intern Med 2005;142(10):805-812.
24. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats [editorial]. J Infect Dis 2011;203:6-10.
25. Feinstein AR, Wood HF, Epstein JA, et al. A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children: results of the first three years of the study, including methods for evaluating the maintenance of oral prophylaxis. N Engl J Med 1959;260:697-702.
26. Jorup-Rönström C, Briotton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection 1987;15(2):105-106.
27. Sjöblom AC, Eriksson B, Jorup-Rönström C, et al. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993;21:390-393.
28. Wang Jh, Liu Yc, Cheng Dl, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis 1997;25:685-689.
29. Baddour LM. Recurrent cellulitis after saphenous venectomy for coronary artery bypass graft surgery. In: Baron EL, ed. UpToDate. October 28, 2010 ed; 2011. http://www.uptodate.com/contents/recurrent-cellulitis-after-saphen -ous-venectomy-for-coronary-artery-bypass-graft-surgery?source=search_result&selectedTitle 3%7E10. Accessed May 20, 2011.
30. Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2005;54 (RR-7):1-10.
31. Price VE, Blanchette VS, Ford-Jones EL. The prevention and management of infections in children with asplenia or hyposplenia. Infect Dis Clin North Am 2007;21(3):697-710, viii-ix.
32. American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000;106(2, pt 1):362-366.
33. Montalembert M, Lenoir G. Antibiotic prevention of pneumococcal infections in asplenic hosts: admission of insufficiency. Ann Hematol 2004;83:18-21.
34. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett‘s Principles and Practices of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier;2010:957-985.
35. Lee BB, Simpson JM, Craig JC, Bhuta T. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev 2007;(4):CD003265.
36. Raz R, Chazan B, Dan M. Cranberry juice and urinary tract infection. Clin Infect Dis 2004;38:1413-1419.
37. Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2008;(1):CD001321.
38. Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrotta C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004;(3):CD001209.
39. Raz R, Stamm WE. A controlled trial of intravaginal estriol in post-menopausal women with recurrent urinary tract infections. N Engl J Med 1993;329:753-756.
40. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010;(9):CD002907.
41. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-724.
42. Novella M, Sola R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997;25:532-536.
43. Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of pontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995;22:1171-1174.
44. Singh N, Gayowski T, Yu V, et al. Trimethoprim-sulfamethox-azole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995;122:595-598.
45. Cohen MJ, Sahar T, Benenson S, et al. Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding. Cochrane Database Syst Rev 2009;(2):CD004791.
46. Das A. A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis. Am J Gastroenterol 1998;93:1895-1900.
47. Baron MJ, Madoff LC. Pancreatic infection. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett‘s Principles and Practices of Infectious Diseases Vol 1. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:1045-1053.
48. Villatoro E, Mulla M, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev. 2010;(5):CD002941.
49. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006;101:2379-2400.
50. Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. Gastroenterology 2007;132(5):2022-2044.
51. Kizer K. Animal bites. In: Gorbach S, Bartlett J, Blacklow N, eds. Infectious Diseases 2nd ed. Philadelphia, PA: Saunders; 1998:1559-1563.
52. Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. N Engl J Med 1999;340:85-92.
53. Cummings P. Antibiotics to prevent infection in patients with dog bite wounds: a meta-analysis of randomized trials. Ann Emerg Med. 1994;23:535-540.
54. Fleisher GR. The management of bite wounds. N Engl J Med 1999;340:138-140.
55. Dellinger EP, Wertz MJ, Miller SD, et al. Hand infections: bacteriology and treatment: a prospective study. Arch Surg 1988;123:745-750.
56. Centers for Disease Control and Prevention (CDC). Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2006;55:1-34.
57. Centers for Disease Control and Prevention (CDC). Tetanus and pertussis vaccination coverage among adults aged ≥18 years – United States, 1999 and 2008. MMWR Morb Mortal Wkly Rep. 2010;59:1302-1306.
58. Centers for Disease Control and Prevention (CDC). Final 2009 reports of nationally notifiable diseases. MMWR Morb Mortal Wkly Rep 2010;59:1025,1035.
59. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011;60:13-15.
60. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Provisional recommendations for health care personnel on use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) and use of postexposure antimicrobial prophylaxis. http://www.cdc.gov/vaccines/recs/provisional/downloads/use-of-Tdap-in-hcp pdf. Accessed May 20, 2011.
61. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;116:1736-1754.
62. Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007;89:780-785.
63. Steckelberg JM, Osmon DR. Prosthetic joint infections. In: Waldvogel FA, Bisno AL, eds. Infections Associated With Indwelling Medical Devices 3rd ed. Washington, DC: American Society for Microbiology;2000:173-209.
64. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004;351:1645-1654.
65. Ahlberg A, Carlsson A, Lindberg L. Hematogenous infection in total joint replacement. Clin Orthop Relat Res 1978;137:69-75.
66. Bengtson S, Blomgren G, Knutson K, et al. Hematogenous infection after knee arthroplasty. Acta Orthop Scand 1987;58:529-534.
67. Deacon JM, Pagilaro AJ, Zelicof SB, et al. Current concepts review: prophylactic use of antibiotics for procedures after total joint replacement. J Bone Joint Surg Am 1996;78(11):1755-1770.
68. Uçkay I, Pittet D, Bernard L, et al. Antibiotic prophylaxis before invasive dental procedures in patients with arthroplasties of the hip and knee. J Bone Joint Surg Br 2008;90:833-838.
69. Lockhart PB, Loven B, Brennan MT, et al. The evidence base for the efficacy of antibiotic prophylaxis in dental practice. J Am Dent Assoc 2007;138:458-474.
70. Berbari EF, Osmon DR, Carr A, et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. Clin Infect Dis 2010;50:8-16.
71. Wahl M. Myths of dental-induced prosthetic joint infections. Clin Infect Dis 1995;20:1420-1425.
72. Lockhart PB, Brennan MT, Fox PC, et al. Decision-making on the use of antimicrobial prophylaxis for dental procedures: a survey of infectious disease consultants and review. Clin Infect Dis 2002;34:1621-1626.
73. Hanssen AD, Osmon DR. The use of prophylactic antimicrobial agents during and after hip arthroplasty. Clin Orthop Relat Res 1999 Dec;(369):124-138.
74. Little JW. Patients with prosthetic joints: are they at risk when receiving invasive dental procedures? Spec Care Dentist 1997;17(5):153-160.
75. Sandhu SS, Lowry JC, Reuben SF, et al. Who decides on the need for antibiotic prophylaxis in patients with major arthroplasties requiring dental treatment: is it a joint responsibility? Ann R Coll Surg Engl 1997;79:143-147.
76. American Dental Association; American Association of Orthopedic Surgeons. Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc 2003;134(7):895-898.
77. American Association of Orthopedic Surgeons (AAOS). Information statement: antibiotic prophylaxis for bacteremia in patients with joint replacements. http://www.aaos.org/about/papers/advistmt/1033.asp. Accessed May 20, 2011.
78. Oliver G, Lowry A, Vernava A, et al; Standards Task Force; American Society of Colon and Rectal Surgeons. Practice parameters for antibiotic prophylaxis supporting documentation. Dis Colon Rectum 2000;43(9):1194-1200.
79. ASGE Standards of Practice Committee. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc 2008;67(6):791-798.
80. American Urological Association; American Academy of Orthopaedic Surgeons. Antibiotic prophylaxis for urological patients with total joint replacements. J Urol 2003;169:1796-1797.
81. Wolf Jr JS, Bennett C, Dmochowski R, et al. Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis Linthicum, MD: American Urological Association; 2007:1-44.http://www.auanet.org/content/media/antimicroprop08.pdf. Accessed May 20, 2011.
82. Aranda-Michel J, Giannella R. Acute diarrhea: a practical review. Am J Med 1999;106:670-676.
83. Caeiro JP, DuPont HL. Management of travelers’ diarrhoea. Drugs 1998;56(1):73-81.
84. Passaro DJ, Parsonnet J. Advances in the prevention and management of traveler’s diarrhea. Curr Clin Top Infect Dis 1998;18:217-236.
85. Ansdell VE, Ericsson CD. Prevention and empiric treatment of traveler’s diarrhea. Med Clin North Am 1999;83:945-973.
86. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers’ diarrhea. Clin Inf Dis 2002;34(5):628-633.
87. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am 1976;58:453-458.
88. Hauser CJ, Adams CA Jr, Eachempath SR. Prophylactic antibiotic use in open fractures: an evidence-based guideline. Surg Infect (Larchmt) 2006;7(4):379-405.
89. Luchette FA, Bone LB, Born CT, et al; Eastern Association for the Surgery of Trauma (EAST) Working Group. Practice management guidelines for prophylactic antibiotic use in open fractures. Published 1998. Updated in 2009. http://www.east.org/tpg/OpenFxUpdate.pdf. Accessed May 20, 2011.
90. ACOG Committee on Practice Guidelines – Gynecology. Gynecologic Herpes simplex virus infections. Obstet Gynecol 2004;104(5, pt 1):1111-1 117.
91. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010;59(RR-12):1-110.
92. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med.1999; 341(18):1336-1343.
93. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282(1):31-35.
94. Fiore AE, Fry A, Shay D, et al; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(1):1-24.
95. Fiore AE, Shay DK, Broder K, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008;57(RR-7):1-60.
96. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6(4):428-442.
97. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29(11):996-1011.
98. Mangram AJ, Horan TC, Pearson ML, et al; Hospital Infection Control Practices Advisory Committee. Guidelines for the prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999;20(4):250-278.
99. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 1999;56(18):1839-1888.
100. Antimicrobial Prophylaxis for Surgery. Treatment Guidelines from the Medical Letter 2009 June; 7(82):47-52.
101. Sexton DJ. Carbapenems for surgical prophylaxis [editorial]? N Engl J Med 2006;355(25):2693-2695.
102. Bratzler DW, Houck PM. Antimicrobial Prophylaxis for Surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004;38:1706-1715.
103. Edwards FH, Engelman RM, Houck P, et al. The Society of Thoracic Surgeons Practice Guideline Series: antibiotic prophylaxis in cardiac surgery; Part I: duration. Ann Thorac Surg 2006;81:397-404.
104. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons Practice Guideline Series: antibiotic prophylaxis in cardiac surgery; Part II: antibiotic choice. Ann Thorac Surg 2007;83:1569-1576.
105. de Oliveira JC, Martinelli M, Nishioka SA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large prospective, randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2(1):29-34.
106. Sohail MR, Uslan DZ, Khan AH, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis 2007;45(2):166-173.
107. Dobay KJ, Freier D, Albear P. The absent role of prophylactic antibiotics in low-risk patients undergoing laparoscopic cholecystectomy. Am Surg 1999;65(3):226-228.
108. Higgins A, London J, Charland S, et al. Prophylactic antibiotics for elective laparoscopic cholecystectomy: are they necessary? Arch Surg 1999;134(6):611-613.
109. Meijer WS, Schmitz PI, Jeekel J. Meta-analysis of randomized, controlled clinical trials of antibiotic prophylaxis in biliary tract surgery. Br J Surg 1990;77(3):282-290.
110. Baum ML, Anish DS, Chalmers TC, et al. A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. N Engl J Med 1981;305(14):795-799.
111. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins Gynecology. ACOG Practice Bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009;113(5):1180-1189.
112. American College of Obstetricians and Gynecologists (ACOG) Committee. Antimicrobial prophylaxis for cesarean delivery: timing of administration: Obstet Gynecol 2010;116(3):791-792.
113. Simo R, French G. The use of prophylactic antibiotics in head and neck oncological surgery. Curr Opin Otolaryngol Head Neck Surg 2006;14:55-61.
114. Weber RS. Wound infection in head and neck surgery: implications for perioperative antibiotic treatment. Ear Nose Throat J 1997;76(11):790-791, 795-798.
115. Barker FG II. Efficacy of prophylactic antibiotics for craniotomy: a meta-analysis. Neurosurgery 1994;35(3):484-490.
116. Barker FG II. Efficacy of prophylactic antibiotics in spinal surgery: a meta-analysis. Neurosurgery 2002;51(2):391-400.
117. Barker FG II. Efficacy of prophylactic antibiotics against meningitis after craniotomy: a meta-analysis. Neurosurgery 2007;60(5):887-894.
118. Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. Antimicrobial prophylaxis in neurosurgery and after head injury. Lancet 1994;344(8936):1547-1551.
119. Haines SJ, Walters BC. Antibiotic prophylaxis for cerebrospinal fluid shunts: a metanalysis. Neurosurgery 1994;34(1):87-92.
120. Langley JM, LeBlanc JC, Drake J, et al. Efficacy of antimicrobial prophylaxis in placement of cerebrospinal fluid shunts: meta-analysis. Clin Infect Dis 1993;17(1):98-103.
121. Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts: a systematic review. J Neurosurg Pediatr 2008;1:48-56.
122. DeCroos FC, Afshari NA. Perioperative antibiotics and anti-inflammatory agents in cataract surgery. Curr Opin Ophthalmol 2008;19:22-26.
123. Liesegang TJ. Perioperative antibiotic prophylaxis in cataract surgery [published correction appears in Cornea. 2000;19(1):123]. Cornea 1999;18(4):383-402.
124. Gillespie WJ, Walenkamp G. Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures. Cochrane Database Syst Rev. 2001;(1): CD000244.
125. Prokuski L. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg 2008;16:283-293.
126. Homer-Vanniasinkam S. Surgical site and vascular infections: treatment and prophylaxis. Int J Infect Dis 2007;11(suppl 1):S17-S22.
127. Stewart AH, Eyers PS, Earnshaw JJ. Prevention of infection in peripheral arterial reconstruction: a systematic review and meta-analysis. J Vasc Surg 2007;46:148-155.
128. Kluytmans JA, Mouton JW, VandenBergh MF, et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996; 17(12):780-785.
129. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002;346:1871-1877.
130. Rey JR, Axon A, Budzynsak A, et al. Guidelines of the European Society of Gastrointestinal Endoscopy (ESGE) antibiotic prophylaxis for gastrointestinal endoscopy. Endoscopy 1998;30(3):318-324.
131. Gernaat-van der Sluis AJ, Hoogenboom-Verdegaal AMM, Edixhoven PJ, et al. Prophylactic mupirocin could reduce orthopedic wound infections: 1,044 patients treated with mupirocin compared with 1,260 historical controls. Acta Orthop Scand 1998;69:412-414.
132. Centers for Disease Control and Prevention (CDC). Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recom Rep 1995;44(RR-12):1-13.
133. Centers for Disease Control and Prevention (CDC). Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997;46(27):626-628;635.
134. Centers for Disease Control and Prevention (CDC). Reduced susceptibility of Staphylococcus aureus to vancomycin – Japan, 1996. MMWR Morb Mortal Wkly Rep. 1997;46(27):624-626.
135. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus with reduced susceptibility to vancomycin – United States, 1997 [published correction appears in MMWR Morb Mortal Wkly Rep. 1997;46:851]. MMWR Morb Mortal Wkly Rep 1997;46(33):765-766.
136. Southorn PA, Plevak DJ, Wright AJ, et al. Adverse effects of vancomycin administered in the perioperative period. Mayo Clin Proc 1986;61:721-724.
137. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 1961;50:161-168.
138. Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical wound infection. N Engl J Med 1992;326(5):281-286.
139. Zanetti G, Giardina R, Platt R. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis 2001;7:828-831.
140. Surgical Care Improvement Project (SCIP). QualityNet Web site. http://www.aha.org/aha/issues/Quality-and-Patient-Safety/scip.html. Accessed May 20, 2011.
141. Wright TI, Baddour LM, Berbari EF, et al. Antibiotic prophylaxis in dermatologic surgery: advisory statement 2008. J Am Acad Dermatol 2008;59:464-473.